Sanofi-Aventis said on Tuesday the European Commission had endorsed the positive opinion of the European Medicines Evaluation Agency (EMEA) for its anti-obesity drug Acomplia (rimonabant) to include type 2 diabetes trial results into the European label (section 5.1). The update is based on the results of the SERENADE study, which showed rimonabant 20 mg significantly improved glycemic control in newly diagnosed naive type 2 diabetic patients, the statement said.
The study also demonstrated that rimonabant 20mg had additional benefits on cardio-metabolic risk factors beyond diabetes.
